1-(3-氯苯基)-2-硫脲 | 4947-89-1

• 物质功能分类: 化学试剂 - 有机试剂 - 硫脲
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-(3-氯苯基)-2-硫脲
• 中文别名: 3-氯苯硫脲；3-氯苯(基)硫脲
• 英文名称: 1-(3-chlorophenyl)-2-thiourea
• 英文别名: 1-(3-chlorophenyl)thiourea；(3-chlorophenyl)thiourea；N-(3-chlorophenyl)thiourea；1-(m-chlorophenyl)thiourea；N-(m-Chlor-phenyl)-thioharnstoff
• CAS: 4947-89-1
• 化学式: C₇H₇ClN₂S
• mdl: MFCD00022165
• 分子量: 186.665
• InChiKey: LSYZRUOXXOTVAV-UHFFFAOYSA-N

物化性质

• 熔点：
  137-138 °C
• 沸点：
  296.7±42.0 °C(Predicted)
• 密度：
  1.441
• 稳定性/保质期：
  在常温常压下保持稳定。

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  70.1
• 氢给体数：
  2
• 氢受体数：
  1

安全信息

• 危险等级：
  6.1
• 危险品标志：
  T+,T
• 安全说明：
  S22,S28A,S36/37/39,S45
• 危险类别码：
  R28
• 海关编码：
  2930909090
• 危险品运输编号：
  2811
• RTECS号：
  YS7000000
• 包装等级：
  II
• 危险类别：
  6.1
• 危险性防范说明：
  P264,P270,P301+P310+P330,P405,P501
• 危险性描述：
  H300
• 储存条件：
  常温、避光、通风干燥处，密封保存。

SDS

Name:	1-(3-Chlorophenyl)-2-thiourea Material Safety Data Sheet
Synonym:
CAS:	4947-89-1

Section 1 - Chemical Product MSDS Name:1-(3-Chlorophenyl)-2-thiourea Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
4947-89-1	1-(3-Chlorophenyl)-2-thiourea		unlisted

Hazard Symbols: T+
Risk Phrases: 28 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Very toxic if swallowed. Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May be fatal if swallowed. May cause irritation of the digestive tract.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid immediately. Wash mouth out with water.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Poison room locked.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 4947-89-1: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: cream
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 137 - 138 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water: Insoluble.
Specific Gravity/Density:
Molecular Formula: C7H7ClN2S
Molecular Weight: 186.67

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, carbon monoxide, oxides of nitrogen, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 4947-89-1: YS7000000 LD50/LC50:
CAS# 4947-89-1: Oral, rat: LD50 = 25 mg/kg.
Carcinogenicity:
1-(3-Chlorophenyl)-2-thiourea - Not listed by ACGIH, IARC, or NTP.
Other:
See actual entry in RTECS for complete information.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.*
Hazard Class: 6.1
UN Number: 2811
Packing Group: II
IMO
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: II
RID/ADR
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing group: II

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: T+
Risk Phrases:
R 28 Very toxic if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 22 Do not breathe dust.
S 28A After contact with skin, wash immediately with
plenty of water.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 4947-89-1: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 4947-89-1 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 4947-89-1 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-(3-氯苯基)-2-硫脲 在 盐酸 作用下， 以 乙醇 为溶剂， 反应 2.0h， 生成 1-(3-chlorophenyl)-4,6-dimethyl-2-(methylthio)pyrimidin-1-ium methyl sulfate
  参考文献：
  名称：

  Korohoda, Maria Jolanta; Slomska, Elzbieta; Szczurek, Halina, Polish Journal of Chemistry, 1989, vol. 63, # 1-3, p. 165 - 171

  摘要：

  DOI：
• 作为产物：
  描述：

  m-chlorophenyldithiocarbamic acid triethylamine salt 在 碘苯二乙酸 、 氨 作用下， 以 水 、 乙腈 为溶剂， 反应 0.5h， 生成 1-(3-氯苯基)-2-硫脲
  参考文献：
  名称：

  由高价碘（III）试剂促进的胺有效合成氰胺

  摘要：

  在单罐策略中，我们已经获得了一种从二硫代氨基甲酸盐/胺开始合成有机氰胺的有效方法。在这种策略中，原位生成的烷基或芳基异硫氰酸酯是通过将二硫代氨基甲酸盐与二乙酰氧基碘苯（DIB）脱硫而获得的，与氨水反应生成烷基或芳基硫脲，随后再用DIB进行氧化脱硫，从而形成了相应的氰胺。产量。温和的反应条件，较短的反应时间，对环境有益的方案以及所需产物的容易分离，使得本方法学成为制备各种有机氰胺的合适替代方法。

  DOI：

  10.1016/j.tetlet.2009.03.017

文献信息

• Substituted <i>N</i>-Phenylisothioureas:  Potent Inhibitors of Human Nitric Oxide Synthase with Neuronal Isoform Selectivity
  作者：Barry G. Shearer、Shuliang Lee、Jeffrey A. Oplinger、Lloyd W. Frick、Edward P. Garvey、Eric S. Furfine

  DOI：10.1021/jm960785c

  日期：1997.6.1

  has been found to be a potent inhibitor of both the human constitutive and inducible isoforms of nitric oxide synthase. A series of substituted N-phenylisothiourea analogues was synthesized to investigate the structure-activity relationship of this class of inhibitor. Each analogue was evaluated for human isoform selectivity. One analogue, S-ethyl N-[4-(trifluoromethyl)phenyl]isothiourea (39), exhibited

  已经发现S-乙基N-苯基异硫脲（4）是一氧化氮合酶的人组成型和诱导型同工型的有效抑制剂。合成了一系列取代的N-苯基异硫脲类似物，以研究这类抑制剂的构效关系。评价每种类似物的人同工型选择性。一种类似物S-乙基N- [4-（三氟甲基）苯基]异硫脲（39）对神经元同工型的诱导选择性和对内皮衍生的组成型同工型的选择性分别为115倍和29倍。研究表明，取代的N-苯基异硫脲39与L-精氨酸竞争性结合。
• Novel Piperine Derivatives with Antidiabetic Effect as PPAR-γ Agonists
  作者：Chetna Kharbanda、Mohammad Sarwar Alam、Hinna Hamid、Kalim Javed、Sameena Bano、Yakub Ali、Abhijeet Dhulap、Perwez Alam、M. A. Qadar Pasha

  DOI：10.1111/cbdd.12760

  日期：2016.9

  Piperine is an alkaloid responsible for the pungency of black pepper. In this study, piperine isolated from Piper nigrum L. was hydrolyzed under basic condition to obtain piperic acid and was used as precursor to carry out the synthesis of twenty piperine derivatives containing benzothiazole moiety. All the benzothiazole derivatives were evaluated for their antidiabetic potential by OGT test followed by

  胡椒碱是负责黑胡椒辛辣的生物碱。在这项研究中，从分离胡椒碱胡椒L.碱性条件下进行水解，得到胡椒酸和用作前体进行含有苯并噻唑部分20个胡椒碱衍生物的合成。通过OGT试验评估所有苯并噻唑衍生物的抗糖尿病潜力，然后在STZ诱导的糖尿病模型中评估活性衍生物。观察到二十种新型胡椒碱类似物中有九种（5b，6a-h）与罗格列酮（标准品）相比，具有明显更高的抗糖尿病活性。此外，评估了这些活性衍生物作为PPAR-γ激动剂的作用，证明了其作用机理。还研究了服用活性衍生物后对体重，脂质过氧化和肝毒性的影响，以进一步确立这些衍生物作为治疗糖尿病副作用较小的先导分子。
• Synthesis of 5-acetyl-2-arylamino-4-methylthiazole Thiosemicarbazones under Microwave Irradiation and their in Vitro Anticancer Activity
  作者：Hai-Bo Shi、Wei-Xiao Hu、Wei-Mao Zhang、Yan-Fei Wu

  DOI：10.3184/174751916x14519928918516

  日期：2016.2

  new tri- and tetra-cyclic thiosemicarbazone derivatives were prepared via the condensation of morpholine, piperazine or N-(4-methoxyphenyl)piperazine with seven methyl hydrazine-carbodithioate derivatives of 5-acetyl-2-arylamino-4-methylthiazoles under microwave irradiation. All compounds were tested for their cytotoxic activity in vitro against human gastric, lung and breast cancer cell lines. The results

  通过吗啉、哌嗪或 N-(4-甲氧基苯基)哌嗪与 7 种 5-乙酰基-2-芳氨基-4-甲基噻唑的甲基肼-碳二硫代酯衍生物缩合反应，制备了一系列 21 种新型三环和四环缩氨基硫脲衍生物在微波照射下。测试了所有化合物对人胃癌、肺癌和乳腺癌细胞系的体外细胞毒活性。结果表明，一些化合物显示出中等的抗癌活性。最有效的化合物是吗啉取代的类似物，对人类乳腺癌细胞表现出显着的活性。
• Dimethylformamide Catalyzed Synthesis of Novel Heterocycles-Their Characterization and Antimicrobial Evaluation
  作者：Vijay V. Dabholkar、Sunil R. Patil、Rajesh V. Pandey

  DOI：10.1002/jhet.1073

  日期：2013.3

  Indandione 1 was brominated to yield 2‐bromoIndandione 2, which further reacted with substituted thiocarbamides, carbamides, 2‐aminothiophenols, 2‐aminophenol, and triazole to furnished 3‐substituted aniline‐2‐thia‐4‐aza‐6,7‐benzo‐8‐oxo‐bicyclo[3.3.0]‐1(5),3‐octadiene 3, 3‐substituted aniline‐2‐oxa‐4‐aza‐6,7‐benzo‐8‐oxo‐bicyclo[3.3.0]‐1(5),3‐octadiene 4, 2‐Thia‐5‐aza‐9‐oxo‐3,4‐(3′‐substituted) benzo‐7

  茚满二酮1溴化生成2-溴茚满二酮2，后者进一步与取代的硫代氨基甲酸酯，脲，2-氨基硫酚，2-氨基苯酚和三唑反应生成3取代的苯胺-2-二硫杂-4-氮杂-6,7-苯并呋喃。 -8-氧代双环[3.3.0] -1（5），3-辛二烯3，3-取代的苯胺-2-氧杂-4-氮杂-6,7-苯并-8-氧代-双环[3.3.0 ] -1（5），3-辛二烯4，2 -Thia-5-氮杂-9-oxo-3,4-（3'-取代）苯并-7,8-苯并双环[4.3.0] -1 （6）壬烯5，2-氧杂-5-氮杂-9-氧代（3,4） - （7,8） -二苯并-二环[4.3.0] -1（6）壬烯6，3'-取代-（1'，2'，4'）triazolo [5,6-b] [indeno（2,3-e）]-1,3,4-噻二嗪7， 分别。根据光谱技术阐明了化合物的结构，进一步筛选了具有代表性的化合物的抗菌活性。
• Compounds for treating spinal muscular atrophy
  申请人：PTC Therapeutics Inc.

  公开号：US09617268B2

  公开（公告）日：2017-04-11

  Provided herein are compounds, compositions thereof and uses therewith for treating spinal muscular atrophy. In a specific embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN2 into mRNA that is transcribed from the SMN2 gene. In another specific embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN1 into mRNA that is transcribed from the SMN1 gene. In yet another embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN1 and SMN2 into mRNA that is transcribed from the SMN1 and SMN2 genes, respectively.

  本文提供了用于治疗脊髓性肌萎缩症的化合物、其组合物和使用方法。在一个具体实施例中，本文提供了一种形式的化合物，可用于调节从SMN2基因转录的mRNA中SMN2的外显子7的包含。在另一个具体实施例中，本文提供了一种形式的化合物，可用于调节从SMN1基因转录的mRNA中SMN1的外显子7的包含。在另一个实施例中，本文提供了一种形式的化合物，可用于调节从SMN1和SMN2基因分别转录的mRNA中SMN1和SMN2的外显子7的包含。

表征谱图